CLAIMS

1. A compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:

wherein

X and Z each represent CH or N;

 R^1 , R^2 , and R^3 , which may be the same or different, represent a hydrogen atom, c_{1-6} alkyl, c_{1-6} alkoxy, c_{2-6} alkenyl, C_{2-6} alkynyl, nitro, ox amino, which C_{1-6} alkyl, C_{1-6} alkoxy, C_{2-6} alkenyl, and C_{2-6} alkynyl are optionally substituted by a halogen atom; hydroxyl; C1-4 alkoxy; C1-4 alkoxycarbonyl; amino on which one or two hydrogen atoms are optionally substituted by C_1 alkyl optionally substituted by hydroxyl or C_{1-4} alkoxy; group $R^{12}R^{13}N$ -C(=0)-0- wherein R^{12} and R^{13} , which may be the same or different, represent a hydrogen atom or C_{1-4} alkyl which alkyl is optionally substituted by hydroxyl or C1-4 alkoxy; or group R^{14} -(S)m- wherein R^{14} represents a seten-membered unsaturated threesaturated or to carbocyclic or heterocyclic group optionally substituted by C_{1-4} alkyl and m is 0 or 1;

R4 represents a hydrogen atom;

 R^5 , R^6 , R^7 , and R^8 , which may be the same or different, represent a hydrogen atom, a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, nitro, or amino, provided that R^5 , R^6 , R^7 , and R^8 do not simultaneously represent a hydrogen atom;

B

 R^9 and R^{10} , which may be the same or different, represent a hydrogen atom, C_{1-6} alkyl, or C_{1-4} alkylcarbonyl, the alkyl portion of which C_{1-6} alkyl or C_{1-4} alkylcarbonyl is optionally substituted by a halogen atom; C_{1-4} alkoxy; amino which is optionally substituted by C_{1-4} alkyl optionally substituted by C_{1-4} alkoxy; or a saturated or unsaturated three— to seven-membered carbocyclic or heterocyclic group; and

 R^{11} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-6} alkoxy), or R^{15} -(CH_2)n- wherein n is an integer of 0 to 4 and R^{15} represents a saturated or unsaturated three- to seven-membered carbocyclic or heterocyclic group which is optionally substituted by a halogen atom, C_{1-6} alkyl, or C_{1-6} alkoxy and is optionally condensed with other saturated or unsaturated three- to seven-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

- 2. The compound according to claim 1, wherein R^1 , R^9 , and R^{10} represent a hydrogen atom.
- 3. The compound according to claim 1, wherein R^1 represents a hydrogen atom and one of or both R^9 and R^{10} represent a group other than a hydrogen atom.
- 4. The compound according to claim 1, wherein X represents N or CH and Z represents CH.
- 5. A compound represented by formula (Ia) or a pharmaceutically acceptable salt or solvate thereof:

pulso

R27 R23 **R26** R25 R21 (la)

wherein

X represents CH or N;

R21 and R22, which may be the same or different, represent unsubstituted C₁₋₆ alkoxy or group R³¹-(CH₂)p-0wherein R^{31} represents a halogen atom, hydroxyl, C_{1-4} alkoxy, C_{1-4} alkoxycarbohyl, amino on which one or two hydrogen atoms are optionally substituted by C1-4 alkyl optionally substituted by hydroxyl or C1-4 alkoxy, group $R^{12}R^{13}N-C(=0)-0-$ wherein R^{12} and R^{13} , which may be the same or different, represent a hydrogen atom or C1-4 alkyl which alkyl is optionally substituted by hydroxyl or C1-4 or group R14-(S)m- wherein R14 represents a unsaturated three to seven-membered saturated or carbocyclic or heterocyclic group optionally substituted by C14 alkyl and m is 0 or 1; and p is an integer of 1 to 6;

 R^{23} , R^{24} , R^{25} , and R^{26} , which may be the same or different, represent a hydrogen atom, a halogen atom, C1-4 alkyl, C_{1-4} alkoxy, C_{1-4} alkylthio, nitro or amino, provided that R23, R24, R25, and R26 do not simultaneously represent a hydrogen atom;

R²⁷ and R²⁸, which may be the same or different, atom, alkyl, hydrogen C_{1-6} represent a alkylcarbonyl, the alkyl portion of which C_{1-6} alkyl or C_{1-} 4 alkylcarbonyl is optionally substituted by a halogen atom; C, alkoxy; amino which is optionally substituted by C_{1-4} alkyl optionally substituted by C_{1-4} alkoxy; or saturated or unsaturated threeto seven-membered

carbocyclic or heterocyclic group; and

 R^{30} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C1-4 alkoxy), or R^{32} -(CH₂)q- wherein q is an integer of 0 to 4 R32 represents a saturated or unsaturated sixmembered carbocyclic or keterocyclic group which is optionally substituted by a halogen atom, C1-4 alkyl, or condensed with other C_{1-4} alkoxy and is optionally unsaturated five- or saturated or six-membered carbocyclic ring or heterocyclic ring to form a bicyclic ring.

6. The compound according to claim 5, wherein R^{21} and R²² represent unsubstituted C₁₋₄ alkoxy.

 $\uparrow_{f v}$ The compound according to claim 5, wherein any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group R31-(CH2)p-O-.

- 8. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents a halogen atom.
- 9. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents a chlorine atom or a fluorine atom.
- 10. The compound according to claim 5, wherein at least one of R^{23} , R^{24} , R^{25} , and R^{26} represents C_{1-4} alkyl.
- 11. The compound according to claim 5, wherein two of R²³, R²⁴, R²⁵, and R²⁶ represent methyl and the remaining two represent a hydrogen atom.
- 12. The compound according to claim 5, wherein at least one of R23, R24, R25, and R26 represents nitro, amino,

 C_{1-4} alkoxy, or C_{1-4} alkylthio.

- 13. The compound according to claim 5, wherein R^{23} , R^{25} , and R^{26} represent a hydrogen atom and R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, nitro, or amino.
- 14. The compound according to claim 5, wherein both R^{27} and R^{28} represent a hydrogen atom.
 - 15. The compound according to claim 5, wherein any one of or both R^{27} and R^{28} represent a group other than a hydrogen atom.
 - 16. The compound according to claim 5, wherein X represents CH or N;

R²¹ and R²² represent unsubstituted C₁₋₄ alkoxy;

R²³, R²⁵, and R²⁶ represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

R²⁷ and R²⁸ represent a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

17. The compound according to claim 5) wherein X represents CH or N;

 R^{21} and R^{22} represent unsubstituted C_{1-4} alkoxy;

 R^{23} , R^{25} , and R^{26} represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

any one of or both R^{27} and R^{28} represent a group other than a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2}

alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

18. The compound according to claim 5, wherein X represents CH or N;

 R^{21} and R^{22} represent unsubstituted C_{1-4} alkoxy;

 R^{23} , R^{25} , and R^{26} represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

R²⁷ represents a hydrogen atom;

 R^{28} represents a group other than a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

19. The compound according to claim 5, wherein X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group R^{31} -(CH_2)p-O-;

 R^{23} , R^{25} , and R^{26} represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alky), C_{1-4} alkoxy, or nitro;

 R^{27} and R^{28} represent a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which

phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

- 20. The compound according to claim 19, wherein R^{21} represents unsubstituted C_{1-4} alkoxy and R^{22} represents group R^{31} -(CH₂)p-O-.
- 21. The compound according to claim 19 or 20, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14} -(S)m- wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 22. The compound according to any one of claims 19 to 21, wherein p is 1.
- 23. The compound according to any one of claims 19 to 21, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).
- 24. The compound according to any one of claims 19 to 21, wherein R^{31} represents $group R^{14}-(S)m-$ wherein R^{14} six-membered heterocyclic represents an unsaturated containing two nitrogen atoms one or group optionally substituted by C1-4 alkyl and m is 0 (zero) and p is 1.
 - 25. The compound according to \claim 23 or 24,

Sub AB wherein R^{14} represents optionally substituted pyridyl.

26. The compound according to claim 5, wherein X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group R^{31} -(CH_2)p-O-;

R²³, R²⁵, and R²⁶ represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

any one of or both R^{27} and R^{28} represent a group other than a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

- 27. The compound according to claim 26, wherein R^{21} represents unsubstituted C_{1-4} alkoxy and R^{22} represents group R^{31} -(CH₂)p-O-.
- 28. The compound according to claim 26 or 27, wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14} —(S)m— wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.
 - 29. The compound according to any one of claims 26

50b A7 to 28, wherein p is 1.

- 30. The compound according to any one of claims 26 to 28, wherein R^{31} represents group R^{14} -(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).
- 31. The compound according to any one of claims 26 to 28, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.
- 32. The compound according to claim 30 or 31, wherein \mathbb{R}^{14} represents optionally substituted pyridyl.
 - 33. The compound according to claim 5, wherein X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} alkoxy and the other represents group $R^{31}-(CH_2)p-0-$;

R²³, R²⁵, and R²⁶ represent a hydrogen atom;

 R^{24} represents a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

R²⁷ represents a hydrogen atom;

 R^{28} represents a group other than a hydrogen atom; and

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{32}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

34. The compound according to claim 33, wherein R21

represents unsubstituted C_{1-4} alkoxy and R^{22} represents group R^{31} -(CH₂)p-O-.

SUD A8

- wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14} —(S)m— wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 36. The compound according to any one of claims 33 to 35, wherein p is 1.
- 37. The compound according to any one of claims 33 to 35, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).
- 38. The compound according to any one of claims 33 to 35, wherein R^{31} represents group R^{14} -(S)m- wherein R^{14} six-membered heterocyclic unsaturated represents an nitrogen atoms and containing one o/r two group optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.
- 39. The compound according to claim 37 or 38, wherein R^{14} represents optionally substituted pyridyl.
 - 40. The compound according to claim 5, wherein X represents CH or N;

any one of R^{21} and R^{22} represents unsubstituted C_{1-4} always and the other represents group R^{31} -(CH_2)p-O-;

 \mathbb{R}^{23} and \mathbb{R}^{26} represent a hydrogen atom;

 R^{24} and R^{25} represent a halogen atom, C_{1-4} alkyl, C_{1-4} alkoxy, or nitro;

R²⁷ and R²⁸ represent a hydrogen atom;

 R^{29} represents C_{1-6} alkyl, C_{2-6} alkenyl, or C_{2-6} alkynyl (which C_{1-6} alkyl, C_{2-6} alkenyl, and C_{2-6} alkynyl each are optionally substituted by a halogen atom or C_{1-4} alkoxy), or $-(CH_2)q-R^{30}$ wherein q is an integer of 0 or 1 and R^{32} represents phenyl, pyridyl, or naphthyl which phenyl, pyridyl, and naphthyl are optionally substituted by a halogen atom, C_{1-4} alkyl, or C_{1-4} alkoxy.

- 41. The compound according to claim 40, wherein R^{21} represents unsubstituted C_{1-4} alkoxy and R^{22} represents group $R^{31}-(CH_2)p-0-$.
- wherein R^{31} represents hydroxyl, amino on which one or two hydrogen atoms are optionally substituted by C_{1-4} alkyl optionally substituted by hydroxyl, or group R^{14} —(S)m— wherein R^{14} represents a saturated or unsaturated five-membered heterocyclic group containing 1 to 4 nitrogen atoms and optionally substituted by C_{1-4} alkyl, or a saturated or unsaturated six-membered heterocyclic group containing one or two hetero-atoms selected from nitrogen and oxygen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero); and p is an integer of 1 to 4.
- 43. The compound according to any one of claims 40 to 42, wherein p is 1.
- 44. The compound according to any one of claims 40 to 42, wherein R^{31} represents group R^{14} -(S)m- wherein R^{14} represents an unsaturated six-membered heterocyclic

SU A9

group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero).

- 45. The compound according to any one of claims 40 to 42, wherein R^{31} represents group $R^{14}-(S)m-$ wherein R^{14} represents an unsaturated six-membered heterocyclic group containing one or two nitrogen atoms and optionally substituted by C_{1-4} alkyl and m is 0 (zero) and p is 1.
- 46. The compound according to claim 44 or 45, wherein R14 represents optionally substituted pyridyl.
- 47. The compound according to claim 1, which is a compound selected from the group consisting of the following compounds or a pharmaceutically acceptable salt or solvate thereof:
- (13) N-{2-chlord-4-[(6,7-dimethoxy-4-quinolyl)oxy]-phenyl}-N'-propylurea;
- (51) N-(2-chloro-4-{[6-methoxy-7-(2-morpholino-ethoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl) urea;
- (62) N-{2-chloro-4-(6,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-propylurea;
- (76) N-{2-chloro-4-[\delta,7-dimethoxy-4-quinazolinyl)-oxy]phenyl}-N'-ethylurea;
- (117) N-{2-chloro-4-[(6,7-dimethoxy-4-quinazo-linyl)oxy]phenyl}-N'-methyluxea;
- (119) N-(2-chloro-4-{[6\methoxy-7-(3-morpholino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;
- (135) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-propylurea;
- (142) N-(2-chloro-4-{[6-methoxy-7-(3-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
- (143) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy}phenyl)-N'\propylurea;
 - (144) $N-(2-\text{chloro}-4-\{[6-\text{metho}xy-7-(2-\text{morpholino-})]\}$

```
ethoxy)-4-quinolyl]oxy}phenyl)-N'-propylurea;
               (145) N-[2-chloro-4-{(6-methoxy-7-[2-(1H-1,2,3-
triazol-1-x1)ethoxy]-4-quinolyl}oxy)phenyl]-N'-
propylurea;
               (146) N-[2-chloro-4-(7-\{[2-(1H-1-imidazolyl)-
ethoxy]-6-methoxy-4-quinolyl}oxy)phenyl]-N'-propylurea;
               (148) N-12-chloro-4-(6-methoxy-7-{[2-(4-methyl-
piperazino)ethoxy]-4-quinolyl}oxy)phenyl]-N'-propylurea;
               (149) N-(2 \leftarrow 10^{-4} - \{[7-(2-hydroxyethoxy)-6-
methoxy-4-quinolyl]oxy}phenyl)-N'-propylurea;
               (151) N-(2-dhloro-4-\{[6-methoxy-7-(3-morpholino-4-1]\})
propoxy)-4-quinolylloxyphenyl)-N'-propylurea;
               (152) N-[2-ch] or 0-4-(6-methoxy-7-\{[3-(4-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methyl-methy
piperazino)propoxy] \dagged4-quinolyl\oxy)phenyl]-N'-
propylurea;
               (153) N-[2-chloro-4-(6-methoxy-7-{[3-(1H-1,2,3-
triazol-1-yl)propoxy]-4-quinolyl}oxy)phenyl]-N'-
propylurea;
               (157) N-\{2-\text{chloro}/4-[(7-\{3-[(2-\text{hydroxyethyl})-
(methyl)amino]propoxy}-6\_methoxy-4-quinolyl)oxy]-
phenyl}-N'-propylurea;
               (159) N-\{2-\text{chloro}-4\} [(6-methoxy-7-\{[5-(1H-1,2,3-
triazol-1-yl)pentyl]oxy}-4\-quinolyl)oxy]phenyl}-N'-
propylurea;
               (160) N-[2-chloro-4-(\forall-{[4-(1H-1-imidazolyl)-
butoxy]-6-methoxy-4-quinoly1\soxy)phenyl]-N'-propylurea;
               (162) N-(2-chloro-4-\{[6]-methoxy-7-(2-morpholino-
ethoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-
phenyl)urea;
               (163) N-(2-\text{chloro}-4-\{[6-\text{methoxy}-7-(3-\text{morpholino}-4-(3-\text{morpholino}-4)\})\}
propoxy)-4-quinazolinyl]oxy}phenyl)-N'-(2,4-difluoro-
phenyl)urea;
              (164) N-[2-chloro-4-(6-methoxy-7-{[3-(4-methyl-
piperazino)propoxy]-4-quinazolinyl\oxy)phenyl]-N'-(2,4-
difluorophenyl)urea;
              (165) N-\{2-chloro-4-[(7-\{3-[(2+hydroxyethyl)-
```

(methyl)amino]propoxy}-6-methoxy-4-qu\u00e4inazolinyl)oxy]-

phenyl}-N'\-(2,4-difluorophenyl)urea;

- (168) N-(2-chloro-4-{[6-methoxy-7-(3-morpholino-propoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)-urea;
- (169) N\(2-chloro-4-{[6-methoxy-7-(3-pyridylmethoxy)-4-quinolyl]oxy}phenyl)-N'-(2,4-difluorophenyl)urea;
- (170) $N-[2-chloro-4-(6-methoxy-7-\{[2-(1H-1,2,3-triazol-1-yl)ethoxy]-4-quinolyl)oxy)phenyl]-N'-(2,4-difluorophenyl)urea;$
- (184) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyl]oxy}phenyl)-N'-methylurea;
- (185) N-(2-chloro-4-{[6-methoxy-7-(3-piperidino-propoxy)-4-quinazolinyt]oxy}phenyl)-N'-ethylurea; and
- (186) N-(2-chloro-4-{[6-methoxy-7-(4-pyridyl-methoxy)-4-quinolyl]oxy)phenyl)-N'-(2,4-difluorophenyl)-urea.
- 48. A pharmaceutical composition comprising as active ingredient the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof.
- 49. The pharmaceutical composition according to claim 48, for use in the treatment of a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.
- 50. Use of the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a therapeutic agent for use in the treatment of a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma.

- 51. A method for treating a disease selected from the group consisting of tumor, diabetic retinopathy, chronic rheumatism, psoriasis, atherosclerosis, and Kaposi's sarcoma, comprising the step of administering an effective amount of the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof, together with a pharmaceutically acceptable carrier, to mammals.
- 52. A method for inhibiting the angiogenesis of target blood vessels, comprising the step of making the compound according to any one of claims 1 to 47 or a pharmaceutically acceptable salt or solvate thereof in contact with vascular endothelial cells of the target blood vessels.